Premarket Overview & Macroeconomic Trends
Major U.S. index futures edged higher in premarket trading on June 26, 2025, though gains moderated slightly after weekly unemployment claims came in at 236,000 - below the expected 245,000. This reflects continued market sensitivity to Federal Reserve policy signals.
Key developments:
- Fed Chair Jerome Powell noted declining economic data reliability may impact decisions (June 24 Congressional testimony)
- Boston Fed President Susan Collins favors late-year rate cuts but warns tariffs could fuel inflation
- Nomura strategist Charlie McElligott predicts volatility control funds may inject $100B+ into stocks
Premarket Movers:
- AMD (+3%)
- Nvidia (+2%)
- Micron (+2%)
- Lixiang Auto (+1%)
- NetEase (-1%)
| Metric | Weekly Data | Expectation | Prior (Revised) |
|---|---|---|---|
| Unemployment Claims | 236K | 245K | 246K |
| Nasdaq 100 Futures | +0.8% | - | +1.5% (6/24) |
| S&P 500 Futures | +0.6% | - | +1.1% (6/24) |
Nvidia's Robotics Breakthrough
Nvidia gained 1% premarket, maintaining its $3.77 trillion market cap as CEO Jensen Huang declared robotics the "next trillion-dollar opportunity" after AI. The company's automotive/robotics revenue grew 72% YoY to $567M in Q1 2025, though it remains just 1% of total revenue.
Investment Considerations:
👉 Why Nvidia's valuation matters for tech investors
- 70x P/E ratio demands sustained growth
- Synergies between data center and autonomous tech
- Competition in AI processors intensifying
| Segment | Q1 2025 | Q1 2024 | Growth |
|---|---|---|---|
| Auto/Robotics | $567M | $330M | +72% |
| Data Center | 2x | N/A | 100%+ |
| Market Cap (6/25) | $3.77T | $2.50T | +50.8% |
Micron's AI-Driven Growth
Micron jumped 2% after crushing earnings expectations:
- Q3 revenue: $9.3B (+37% YoY) vs. $8.85B expected
- EPS: $1.91 vs. $1.60 consensus
- DRAM sales hit record highs
CEO Sanjay Mehrotra emphasized AI-driven demand, with HBM investments expected to comprise 20% of 2026 revenue. The company issued strong Q4 guidance of $10.7B revenue.
| Metric | Q3 2025 | Expectation | Q4 Guidance |
|---|---|---|---|
| Revenue | $9.3B | $8.85B | $10.7B |
| EPS | $1.91 | $1.60 | $2.50 |
| DRAM Revenue | 68% | 65% | 70% est. |
Altimmune's Clinical Setback
The biotech stock cratered 62% after disappointing Phase IIb MASH trial results for pemvidutide:
- Fibrosis improvement: 31.8%-34.5% vs. 25.9% placebo
- Weight loss effects were significant (5-6.2% vs. 1% placebo)
- CEO Vipul Agarwal pledged to continue obesity studies
Implications:
- High bar for competing against Lilly/Novo's GLP-1 drugs
- Need for clearer differentiation in metabolic treatments
Crypto Policy Shift
FHFA's directive to study crypto mortgages boosted select stocks:
- Crane Holdings: +4%
- SharpLink Gaming: +2%
- Bit Digital: -15% on $150M ETH purchase plan
Regulatory Context:
👉 How crypto policies impact tech investments
- Potential $230B mortgage market access
- Political push for "Crypto Capital" status
- Remaining volatility risks
Key Takeaways
- Tech Leadership: Nvidia/Micron benefit from AI infrastructure buildout
- Biotech Risk: Altimmune shows drug development volatility
- Policy Impact: Crypto gains government endorsement
- Macro Caution: Fed policy remains market driver
FAQs
Q: Why is Nvidia expanding into robotics?
A: With AI chip dominance established, robotics represents the next trillion-dollar market, particularly in autonomous vehicles.
Q: What drove Micron's earnings beat?
A: AI server demand created DRAM shortages, allowing price increases and record revenues.
Q: Can Altimmune recover?
A: While MASH results disappointed, the weight loss data may support future obesity trials.
Q: How significant is the crypto mortgage policy?
A: It potentially opens traditional finance to crypto assets, but implementation details remain unclear.